BridgeBio Pharma (FRA:2CL) EPS without NRI: €-3.08 (TTM As of Mar. 2026)


FRA:2CL BridgeBio Pharma Inc FRA:2CL
67 GF Score
Price €67.60
GF Value €127.74
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is BridgeBio Pharma EPS without NRI?

BridgeBio Pharma FRA:2CL +4.77% 67 EPS without NRI is €-3.08 as of Mar. 2026. GuruFocus rates FRA:2CL with a GF Score™ of 67/100 and a GF Value™ of €127.74 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 1,170 Biotechnology companies, BridgeBio Pharma ranks worse than 78.63% on this metric.

BridgeBio Pharma's earnings per share without non-recurring items for the three months ended in Mar. 2026 was €-0.73. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-3.08.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -7.40% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 1.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for BridgeBio Pharma's EPS without NRI or its related term are showing as below:

FRA:2CL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -125.9   Med: -6.55   Max: 5.9
Current: -7.4

During the past 9 years, BridgeBio Pharma's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 5.90% per year. The lowest was -125.90% per year. And the median was -6.55% per year.

FRA:2CL's 3-Year EPS without NRI Growth Rate is ranked worse than
78.63% of 1170 companies
in the Biotechnology industry
Industry Median: 16.75 vs FRA:2CL: -7.40

BridgeBio Pharma's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.73. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-3.21.

BridgeBio Pharma's EPS (Basic) for the three months ended in Mar. 2026 was €-0.73. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-3.21.


BridgeBio Pharma  (FRA:2CL) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


BridgeBio Pharma EPS without NRI Related Terms


BridgeBio Pharma EPS without NRI Historical Data

* Premium members only.

The historical data trend for BridgeBio Pharma's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Pharma EPS without NRI Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only -3.67 -2.75 -3.58 -3.30 -3.08

BridgeBio Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.71 -0.85 -0.84 -0.67 -0.73

FRA:2CL vs EXEL, IONS, JAZZ: EPS without NRI Comparison

For the Biotechnology subindustry, BridgeBio Pharma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BridgeBio Pharma PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's PE Ratio without NRI falls into.


FRA:2CL
67GF Score
BridgeBio Pharma Inc FRA:2CL
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Pharma EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-3.08 mean?
BridgeBio Pharma (FRA:2CL) has a EPS without NRI of €-3.08 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on BridgeBio Pharma and its competitors. According to the industry distribution chart, BridgeBio Pharma ranks #920 out of 1170 companies in the Biotechnology industry, placing it in the top 78.6%.
Is BridgeBio Pharma's EPS without NRI too high?
BridgeBio Pharma's current EPS without NRI is €-3.08. Based on the distribution chart, BridgeBio Pharma ranks #920 out of 1170 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BridgeBio Pharma has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's EPS without NRI compare to EXEL and IONS?
According to the Biotechnology industry distribution chart, BridgeBio Pharma ranks #920 out of 1170 companies for EPS without NRI. This places BridgeBio Pharma in the lower half of its industry. The industry median EPS without NRI is 16.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.75, based on 1,170 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on BridgeBio Pharma and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Pharma's current EPS without NRI is €-3.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €127.74, compared to a current price of €67.60 — trading 47.1% below its estimated fair value. The current EPS without NRI is €-3.08. BridgeBio Pharma's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current EPS without NRI is €-3.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €67.60 is trading 47.1% below its estimated GF Value™ of €127.74. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

  • EPS without NRI: €-3.08
  • GF Value™: €127.74 vs. price of €67.60 (47.1% below fair value)
  • GF Score™: 67/100 with 8 warning signs

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BridgeBio Pharma Business Description

Other Exchanges BBIO:USA1BBIO:Italy
Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
67GF Score

Get the complete analysis for FRA:2CL

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€67.60
Price
€127.74
GF Value